home > ict > spring 2020 > uk data protection in post-marketing pharmacovigilance
International Clinical Trials

UK Data Protection in Post-Marketing Pharmacovigilance

In the UK, the Data Protection Act (DPA) 2018 governs the processing of personal data and implements the European GDPR: Regulation (EU) 679/20161. The GDPR came into force on 25 May 2018 and replaced the EU Directive 95/46/EC (the Data Protection Directive). Even though the UK has left the EU, the DPA brings GDPR requirements into UK law and extends it to cover legal areas for which the EU does not have oversight. It will remain in force after the UK leaves the EU.

In terms of scope, we need to be aware that the GDPR applies both in and outside of the UK and EU. Health data and other sensitive data cannot be processed without informed consent, unlessan exception applies, but when it comes to fulfilling pharmacovigilance (PV) obligations, processing the data is necessary as stated in Article 9.

In PV, there are two types of data that are subject to regulation:

1. Personal data received from the collection of reports (e.g., adverse event reports by email notifications)

2. Collected data that no longer contain personal data (e.g., subject identifiers replaced in order to pseudonymise the data)

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:

There are no comments in regards to this article.

About the author

Avile Grey is pharmacovigilance professional with an MSc in Pharmacovigilance at the University of Hertfordshire, UK. She has been an active member of the PIPA Training Working Party since 2013.
Print this page
Send to a friend
Privacy statement
News and Press Releases

Myonex Opens New Global Headquarters

Myonex, a leading global clinical trial supply company, marked the opening of its new global headquarters and US operational facility with a ribbon-cutting ceremony on the company’s 14-acre campus.
More info >>

White Papers

The Importance of Critical Temperatures in the Freeze Drying of Pharmaceutical Products

Biopharma Group

Every formulation has a critical temperature, below which it should be cooled for complete solidification and maintained below during primary drying in order to prevent processing defects. To design a freeze drying cycle on a rational basis such information should be identified.
More info >>




©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement